Valeo Financial Advisors’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-6,577
Closed -$359K 519
2022
Q2
$359K Sell
6,577
-1,513
-19% -$83.2K 0.02% 304
2022
Q1
$505K Sell
8,090
-493
-6% -$32.5K 0.03% 327
2021
Q4
$863K Buy
8,583
+649
+8% +$57K 0.05% 210
2021
Q3
$714K Hold
7,934
0.04% 233
2021
Q2
$732K Buy
7,934
+284
+4% +$22.7K 0.04% 203
2021
Q1
$739K Buy
7,650
+3,895
+104% +$402K 0.03% 213
2020
Q4
$196K Buy
3,755
+500
+15% +$20.9K 0.01% 424
2020
Q3
$130K Buy
3,255
+1,908
+142% +$59.7K 0.01% 418
2020
Q2
$22K Sell
1,347
-225
-14% -$3.44K ﹤0.01% 1025
2020
Q1
$17K Buy
1,572
+663
+73% +$9.23K ﹤0.01% 933
2019
Q4
$12K Buy
+909
New +$10.8K ﹤0.01% 1051

Other funds holding FLGT

Valeo Financial Advisors's FLGT Position: Q3 2022 in Review

Valeo Financial Advisors sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 6,577 shares — an estimated $359K sold.

Valeo Financial Advisors first reported a position in FLGT in Q4 2019 and held it in 11 quarters. The position peaked at $863K in Q4 2021. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

  • Valeo Financial Advisors reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
  • Valeo Financial Advisors sold 6,577 Fulgent Genetics shares in Q3 2022, an estimated $359K.
  • Valeo Financial Advisors first reported a position in Fulgent Genetics in Q4 2019 and held it in 11 quarters.
  • Valeo Financial Advisors's Fulgent Genetics position peaked at $863K in Q4 2021.
  • 235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Valeo Financial Advisors's 13F filing for Q3 2022, filed 31 Oct 2022.